Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

MRTX | Mirati Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-12.82	Insider Own	7.69%	Shs Outstand	69.89M	Perf Week	27.05%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-10.01	Insider Trans	88.35%	Shs Float	64.52M	Perf Month	14.85%
Income	-737.54M	PEG	-	EPS next Q	-2.83	Inst Own	90.07%	Short Float / Ratio	14.67% / 7.57	Perf Quarter	8.44%
Sales	27.22M	P/S	103.77	EPS this Y	11.03%	Inst Trans	1.17%	Short Interest	9.46M	Perf Half Y	3.36%
Book/sh	12.50	P/B	3.23	EPS next Y	14.61%	ROA	-67.21%	Target Price	54.00	Perf Year	-42.21%
Cash/sh	11.15	P/C	3.62	EPS next 5Y	82.89%	ROE	-80.13%	52W Range	27.30 - 101.30	Perf YTD	-10.80%
Dividend	-	P/FCF	-	EPS past 5Y	-36.50%	ROI	-95.58%	52W High	-60.10%	Beta	0.87
Dividend %	-	Quick Ratio	5.79	Sales past 5Y	116.57%	Gross Margin	77.11%	52W Low	48.04%	ATR	1.91
Employees	593	Current Ratio	5.85	Sales Q/Q	155.32%	Oper. Margin	-2862.61%	RSI (14)	65.77	Volatility	7.81% 4.99%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	4.35%	Profit Margin	-2709.33%	Rel Volume	1.40	Prev Close	41.00
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Aug 08 AMC	Payout	-	Avg Volume	1.25M	Price	40.42
Recom	1.75	SMA20	13.89%	SMA50	16.86%	SMA200	-1.21%	Volume	767,528	Change	-1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-23	Upgrade	Citigroup	Neutral → Buy	$51 → $48
Aug-09-23	Upgrade	B. Riley Securities	Neutral → Buy	$45
Aug-09-23	Resumed	Piper Sandler	Overweight	$45
Jul-27-23	Initiated	Scotiabank	Sector Underperform
May-25-23	Upgrade	Oppenheimer	Perform → Outperform
Dec-14-22	Initiated	Needham	Hold
Dec-09-22	Downgrade	Citigroup	Buy → Neutral	$121 → $53
Dec-08-22	Downgrade	JP Morgan	Overweight → Neutral	$94 → $65
Dec-08-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$110 → $59
Oct-28-22	Initiated	B. Riley Securities	Neutral	$72
Sep-15-22	Initiated	Piper Sandler	Overweight	$110
Jun-07-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$72
May-20-22	Upgrade	Guggenheim	Neutral → Buy	$115
Feb-01-22	Upgrade	BofA Securities	Underperform → Neutral	$171 → $141
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$187
Sep-23-21	Initiated	Stifel	Buy	$202
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight	$160
Jun-04-21	Upgrade	Citigroup	Neutral → Buy
May-17-21	Downgrade	Oppenheimer	Outperform → Perform
May-10-21	Upgrade	Jefferies	Hold → Buy	$208 → $196

Show Previous Ratings

Sep-09-23 10:35PM	Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer (PR Newswire)
Sep-05-23 04:01PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -5.25%
Aug-29-23 04:00PM	Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
Aug-23-23 04:00PM	Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer (PR Newswire)
Aug-21-23 04:00PM	Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer (PR Newswire)
07:40AM	Loading…
Aug-19-23 07:40AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Aug-16-23 11:02AM	BOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics Inc (GuruFocus.com)
Aug-11-23 04:00PM	Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-10-23 10:12AM	Penn downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly) +5.95%
Aug-09-23 04:01PM	Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit (Investor's Business Daily) +33.09%
04:00PM	Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition (PR Newswire)
11:06AM	Mirati Rockets 31% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit (Investor's Business Daily)
10:56AM	Why Shares of Mirati Therapeutics Are Jumping Wednesday (Motley Fool)
10:41AM	Mirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit (Investor's Business Daily)
10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
09:42AM	Loading…
09:42AM	Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales (Zacks)
08:37AM	Q2 2023 Mirati Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
12:31AM	Mirati Therapeutics Announces Pricing of Upsized Public Offering (PR Newswire)
Aug-08-23 04:58PM	Mirati: Q2 Earnings Snapshot (AP Finance)
04:02PM	Mirati Therapeutics Announces Proposed Public Offering (PR Newswire)
04:01PM	Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates (PR Newswire)
04:00PM	Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek (PR Newswire)
Aug-03-23 04:01PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jul-28-23 02:00AM	Superyacht Dinners and Alleged Insider Tips Ensnare Billionaire (Bloomberg)
Jul-26-23 02:46PM	RPT-UPDATE 6-British billionaire Joe Lewis pleads not guilty to US insider trading charges (Reuters)
02:09PM	UPDATE 6-British billionaire Joe Lewis pleads not guilty to US insider trading charges (Reuters)
01:46PM	UPDATE 5-British billionaire Joe Lewis pleads not guilty to US insider trading charges (Reuters)
Jul-25-23 04:30PM	Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023 (PR Newswire)
Jul-21-23 07:56AM	Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation (PR Newswire) -7.39%
06:19AM	EU regulator declines to back Mirati's lung cancer drug (Reuters)
09:00AM	Loading…
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia) +5.37%
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-28-23 08:29AM	Will Mirati Therapeutics (NASDAQ:MRTX) Spend Its Cash Wisely? (Simply Wall St.)
Jun-23-23 04:00PM	Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director (PR Newswire)
Jun-20-23 08:00AM	Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases (PR Newswire)
Jun-01-23 04:30PM	Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 (PR Newswire)
11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks)
10:23AM	Top Stocks for June 2023 (Investopedia)
May-30-23 08:45PM	Oppenheimer Sees Over 50% Gains in These 2 Stocks Heres Why They Could Soar (TipRanks)
04:00PM	Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting (PR Newswire)
May-25-23 10:15AM	Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting (Benzinga) -12.41%
May-24-23 04:01PM	Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® (PR Newswire)
May-14-23 08:14AM	Growth Investors: Industry Analysts Just Upgraded Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Forecasts By 23% (Simply Wall St.)
May-11-23 06:11AM	Mirati Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 11:53AM	Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up (Zacks)
May-09-23 04:27PM	Mirati: Q1 Earnings Snapshot (AP Finance)
04:01PM	Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates (PR Newswire)
May-08-23 08:30AM	Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies (PR Newswire)
May-05-23 04:00PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-27-23 04:30PM	Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference (PR Newswire)
Apr-26-23 04:33PM	Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors (PR Newswire)
Apr-25-23 04:30PM	Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023 (PR Newswire)
Apr-15-23 09:11AM	Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago (Simply Wall St.)
Apr-03-23 04:00PM	Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs (PR Newswire)
Mar-06-23 04:30PM	Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference (PR Newswire)
Mar-05-23 07:19AM	Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) (Simply Wall St.)
Mar-03-23 08:11PM	Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-02-23 07:56AM	Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 36% Undervaluation? (Simply Wall St.)
Mar-01-23 09:22AM	Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales (Zacks)
Feb-28-23 04:01PM	Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates (PR Newswire)
Feb-21-23 04:30PM	Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference (PR Newswire) -6.22%
Feb-14-23 04:30PM	Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023 (PR Newswire)
Feb-03-23 04:31PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-01-23 04:30PM	Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences (PR Newswire)
Jan-20-23 10:11AM	Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage (Zacks) +6.24%
Jan-19-23 05:00PM	Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133 (PR Newswire)
06:41AM	We're Keeping An Eye On Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate (Simply Wall St.)
Jan-06-23 04:00PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-22-22 04:30PM	Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +5.18%
11:34AM	Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC (Zacks)
08:42AM	Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug (MarketWatch)
03:09AM	Micron, CarMax and Tyson Foods fall premarket; MillerKnoll rises (Investing.com)
Dec-21-22 05:00PM	Mirati announces Adagrasib (KRAZATI) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer (PR Newswire)
Dec-13-22 04:12PM	Stocks Moving the Most Today: Moderna, Pinterest, Trimble, and More (Barrons.com)
04:00PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
09:03AM	Mirati's lung cancer drug gets an accelerated approval (MarketWatch)
08:48AM	Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues (Investor's Business Daily)
06:45AM	Another Competitor For Amgen As FDA Approves Mirati Therapeutics' KRAS Inhibitor For Lung Cancer Setting (Benzinga)
06:29AM	Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC (Zacks)
Dec-12-22 06:41PM	Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation (PR Newswire)
Dec-09-22 06:21AM	These Analysts Think Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Sales Are Under Threat (Simply Wall St.)
Dec-08-22 04:23PM	Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days (Investor's Business Daily) -11.57%
Dec-07-22 04:28PM	Why Shares of Mirati Therapeutics Fell Wednesday (Motley Fool) -30.66%
10:57AM	Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib (Zacks)
Dec-06-22 04:13PM	Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up (Investor's Business Daily) -22.89%
03:44PM	Why Shares of Mirati Therapeutics Fell Tuesday (Motley Fool)
06:11AM	Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy (Benzinga)
01:42AM	UPDATE 1-Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients (Reuters)
Dec-05-22 06:05PM	Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients (Reuters)
06:05PM	Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (PR Newswire)
Dec-02-22 08:00AM	Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study (PR Newswire) +5.19%
Nov-28-22 08:00AM	Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO (PR Newswire)
Nov-24-22 10:22AM	Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations (Zacks)
Nov-23-22 04:14PM	Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle (Investor's Business Daily) +11.31%
07:34AM	Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month (Benzinga)
Nov-22-22 03:17PM	Cancer Drugmaker Mirati Draws Fresh Takeover Interest (Bloomberg) +15.52%
Nov-09-22 09:47AM	Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat (Zacks)
Nov-08-22 05:25PM	Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates (PR Newswire)
04:05PM	Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team (PR Newswire)

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Christensen Jamie	EVP & Chief Scientific Officer	Sep 08	Sale	35.63	2,388	85,084	144,032	Sep 12 05:41 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	1,201,440	33,400,032	3,201,440	Aug 15 09:39 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	1,201,440	33,400,032	3,201,440	Aug 15 09:38 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	57,533	1,599,417	287,866	Aug 15 09:39 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	57,533	1,599,417	287,866	Aug 15 09:38 PM
Hasnain Faheem	Director	Aug 11	Buy	27.80	10,791	299,990	10,791	Aug 14 04:41 PM
Stelzer Laurie	Chief Financial Officer	Jun 02	Sale	37.06	4,647	172,218	80,015	Jun 02 07:15 PM
Christensen Jamie	EVP & Chief Scientific Officer	May 24	Sale	45.29	619	28,035	124,123	May 24 07:38 PM
Cherrington Julie M	Director	Jan 18	Sale	44.66	2,546	113,704	0	Jan 20 09:20 AM
Meek David D.	Chief Executive Officer	Jan 17	Sale	42.38	3,179	134,715	61,792	Jan 19 09:45 AM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 17	Sale	42.38	2,245	95,142	97,878	Jan 19 09:45 AM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 17	Sale	42.38	1,566	66,366	47,223	Jan 19 09:45 AM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 09	Sale	45.37	2,088	94,733	48,789	Jan 10 05:00 PM
BAUM CHARLES M	President,Founder,Head of R&D	Jan 04	Sale	46.60	3,648	169,997	168,777	Jan 05 05:13 PM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 04	Sale	46.60	1,949	90,823	100,123	Jan 05 05:13 PM
BAUM CHARLES M	President,Founder,Head of R&D	Dec 21	Sale	40.42	9,092	367,469	172,425	Dec 21 09:21 PM
Meek David D.	Chief Executive Officer	Dec 21	Sale	40.41	4,616	186,552	64,971	Dec 21 09:20 PM
Hickey Benjamin	EVP, Chief Commercial Officer	Dec 21	Sale	40.41	3,248	131,266	50,877	Dec 21 09:20 PM
Christensen Jamie	EVP, Chief Scientific Officer	Dec 16	Sale	43.00	2,410	103,624	102,072	Dec 20 04:02 PM
Christensen Jamie	EVP, Chief Scientific Officer	Dec 02	Sale	90.19	1,726	155,667	104,482	Dec 05 05:00 PM
BAUM CHARLES M	President,Founder,Head of R&D	Nov 28	Option Exercise	17.41	69,256	1,205,747	197,155	Nov 28 07:01 PM
BAUM CHARLES M	President,Founder,Head of R&D	Nov 28	Sale	100.00	69,256	6,925,600	127,899	Nov 28 07:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRTX | Mirati Therapeutics Inc

Upgrade your FINVIZ experience